Radioreceptor assay for advanced glycosylation end products - PubMed (original) (raw)

Radioreceptor assay for advanced glycosylation end products

S Radoff et al. Diabetes. 1991 Dec.

Abstract

Previous assays for nonenzymatic advanced glycosylation end products (AGEs) formed in tissues and/or circulating in blood are unsatisfactory. Based on our earlier identification of AGE-specific receptors on the macrophagelike tumor cell line RAW 264.7, a new assay system for AGEs has been devised. RAW 264.7 cells were used in competitive radioreceptor assays (RRA) after a 3-day culture in 96-well plates with 1 mu CI/ml [3H]glycine. Bovine serum albumin (BSA), modified extensively by incubation with glucose-6-phosphate in vitro to form AGE-BSA, was labeled with 125I and was used as a model ligand at a concn of 10 micrograms/ml. One unit of AGE was defined as the amount of test protein required to inhibit 50% of the specific binding of [125I]-labeled AGE-BSA to the AGE-receptors of intact RAW 264.7 cells. Nonlabeled AGE-BSA was used as a specific competitor to construct standard curves. The reproducibility of the assay was assessed at AGE levels equivalent to mean, maximum, and minimum levels of sensitivity for assays run on a single day and over an extended period, and the RRA had a reproducibility (coefficient of variation) between 5.9 and 14.7%. Protease hydrolysis of in vitro glycosylated proteins before assay increases the competitive ability of these proteins in proportion to their glycosylation. Little or no AGE cross-reactivity was detected in native BSA, Amadori-BSA, maleylated BSA, formaldehyde-treated BSA, palmitic acid-BSA, and acetylated low-density lipoproteins (acetyl-LDL). Polyanions such as heparin or fucoidan strongly interfere with this receptor binding assay.(ABSTRACT TRUNCATED AT 250 WORDS)

PubMed Disclaimer

Similar articles

• Identification of galectin-3 as a high-affinity binding protein for advanced glycation end products (AGE): a new member of the AGE-receptor complex.
  Vlassara H, Li YM, Imani F, Wojciechowicz D, Yang Z, Liu FT, Cerami A. Vlassara H, et al. Mol Med. 1995 Sep;1(6):634-46. Mol Med. 1995. PMID: 8529130 Free PMC article.
• The receptor for advanced glycation end products mediates the chemotaxis of rabbit smooth muscle cells.
  Higashi T, Sano H, Saishoji T, Ikeda K, Jinnouchi Y, Kanzaki T, Morisaki N, Rauvala H, Shichiri M, Horiuchi S. Higashi T, et al. Diabetes. 1997 Mar;46(3):463-72. doi: 10.2337/diab.46.3.463. Diabetes. 1997. PMID: 9032104
• Glycolaldehyde, a reactive intermediate for advanced glycation end products, plays an important role in the generation of an active ligand for the macrophage scavenger receptor.
  Nagai R, Matsumoto K, Ling X, Suzuki H, Araki T, Horiuchi S. Nagai R, et al. Diabetes. 2000 Oct;49(10):1714-23. doi: 10.2337/diabetes.49.10.1714. Diabetes. 2000. PMID: 11016456
• Receptor-mediated interactions of advanced glycosylation end products with cellular components within diabetic tissues.
  Vlassara H. Vlassara H. Diabetes. 1992 Oct;41 Suppl 2:52-6. doi: 10.2337/diab.41.2.s52. Diabetes. 1992. PMID: 1326453 Review.
• Receptors labeled with gamma-emitting radiotracers.
  Eckelman WC. Eckelman WC. Int J Rad Appl Instrum B. 1986;13(2):135-9. doi: 10.1016/0883-2897(86)90228-x. Int J Rad Appl Instrum B. 1986. PMID: 3021688 Review. No abstract available.

Cited by

• [Non-enzymatic glycation and oxidative stress in chronic illnesses and diabetes mellitus].
  Nawroth PP, Bierhaus A, Vogel GE, Hofmann MA, Zumbach M, Wahl P, Ziegler R. Nawroth PP, et al. Med Klin (Munich). 1999 Jan 15;94(1):29-38. doi: 10.1007/BF03044692. Med Klin (Munich). 1999. PMID: 10081287 Review. German.
• Effects of advanced glycation end-products on the proliferation and differentiation of osteoblast-like cells.
  McCarthy AD, Etcheverry SB, Bruzzone L, Cortizo AM. McCarthy AD, et al. Mol Cell Biochem. 1997 May;170(1-2):43-51. doi: 10.1023/a:1006816223292. Mol Cell Biochem. 1997. PMID: 9144317
• Increased collagen-linked pentosidine levels and advanced glycosylation end products in early diabetic nephropathy.
  Beisswenger PJ, Moore LL, Brinck-Johnsen T, Curphey TJ. Beisswenger PJ, et al. J Clin Invest. 1993 Jul;92(1):212-7. doi: 10.1172/JCI116552. J Clin Invest. 1993. PMID: 8325987 Free PMC article.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Silverchair Information Systems

• Other Literature Sources

  • The Lens - Patent Citations Database

• Research Materials

  • NCI CPTC Antibody Characterization Program